Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. announced today it has completed enrollment for its sustained release dexamethasone (OTX-DP) in a Phase II study under an Investigational New Drug (IND) submission to the Food and Drug Administration (FDA).
Help employers find you! Check out all the jobs and post your resume.